The advisory board also will provide valuable direction as VuCOMP continues to develop a computer-aided detection (CAD) solution for tomosynthesis.
The board is comprised of:
- Debra Copit, M.D., FACR, clinical associate professor of Radiology, Jefferson Medical College, and director of Breast Imaging, Albert Einstein Health Network, Philadelphia, Pa.
- W. Phil Evans, M.D., FACR, clinical professor of Radiology, director of the Center for Breast Care and the George and Carol Poston Professorship in Breast Cancer Research, University of Texas Southwestern, Dallas, Texas.
- Michael Linver, M.D., director of Mammography, X-Ray Associates of New Mexico, P.C., clinical professor of Radiology, University of New Mexico School of Medicine, Albuquerque, N.M.
- Elizabeth Morris, M.D., chief of Breast Imaging Services, Memorial Sloan-Kettering Cancer Center, New York, N.Y.
- Katja Pinker-Domenig, M.D., chief of the Breast Imaging Section, University of Vienna, Vienna, Austria.
- Frank Stöblen, M.D., head of Clinic Gyn. Radiology, Kliniken-Essen Mitte, Essen, Germany.
The company expects the board to expand in the coming months to include additional thought leaders with expertise in breast imaging.
“We are pleased to have such an experienced and knowledgeable medical advisory board to help guide VuCOMP in the development of products,” said VuCOMP President James Pike. “Vital to our success is truly understanding, in great depth, both the clinical needs of our customers, as well as how our products enhance their workflow. Their insights will help us to achieve these objectives.”
To date, VuCOMP has developed and commercialized two breast imaging products, M-Vu CAD and M-Vu Breast Density. M-Vu CAD received U.S. Food and Drug Administration (FDA) approval for digital mammography in October 2012. While mammography CAD systems have been FDA-approved since 1998, recent FDA guidelines significantly have raised the bar for demonstrating CAD effectiveness, and now recommend comprehensive reader studies proving that radiologists are more effective when they use CAD. The VuCOMP system is the first mammography CAD product in the world to achieve FDA approval under these clinical study guidelines, the company claims. M-Vu Breast Density received FDA market clearance in December 2013.
Based in Plano, Texas, VuCOMP Inc. develops advanced cancer detecting technologies.